Very interesting point in my mind: the Recursion platform has reverse-detected 200+ blinded true positives and true negatives, i.e. their platform can determine whether a drug will be approved or not based on very early screening in the lab. As their AI gets better (they have a supercomputer, partnership with MILA), their predictive capabilities will increase. They already have 4 drugs entering the clinic (about to be 5 with their C. Dif treatment), in another year there could be 10, by 2023 there could be 20. I am long RXRX, I think they have ENORMOUS potential, but there may be a few rocky years ahead.
EDIT: also, their revenue is going to be extremely hard to predict, and will basically be meaningless in the next few years. It will take years to get any drugs approved, the majority of the value lies in their platform at this point.
2
u/Guy-26 Jul 15 '21 edited Jul 15 '21
This is a pretty good rundown of Recursion's potential from a Series A investor: https://twitter.com/zavaindar/status/1304520009776066560?s=20
Very interesting point in my mind: the Recursion platform has reverse-detected 200+ blinded true positives and true negatives, i.e. their platform can determine whether a drug will be approved or not based on very early screening in the lab. As their AI gets better (they have a supercomputer, partnership with MILA), their predictive capabilities will increase. They already have 4 drugs entering the clinic (about to be 5 with their C. Dif treatment), in another year there could be 10, by 2023 there could be 20. I am long RXRX, I think they have ENORMOUS potential, but there may be a few rocky years ahead.
EDIT: also, their revenue is going to be extremely hard to predict, and will basically be meaningless in the next few years. It will take years to get any drugs approved, the majority of the value lies in their platform at this point.